- Psoriasis is a skin condition which causes redness and scaly patches on the skin
- The Food and Drug Administration (FDA) approved brodalumab drug for psoriasis treatment
- Brodalumab drug found to be effective in the treatment of moderate-to-severe plaque psoriasis. The drug is available only through Risk Evaluation Mitigation Program (REMS)
The United States Food and Drug Administration (USFDA) has approved Brodalumab drug for the treatment of moderate-to-severe plaque psoriasis.
Psoriasis is an autoimmune disease which causes redness and scaly patches on the skin. Plaque psoriasis is the most common type of psoriasis and is responsible for 80% of the total cases.
Brodalumab drug (Siliq) is administered as an injection. The drug is intended for systemic therapy using substances which can travel through the bloodstream after taking the injection, or ultraviolet therapy and have failed to respond or stopped responding to the other therapies.
"Patients and their health care providers should discuss the benefits and risks of brodalumab drug before considering treatment."
Brodalumab - Mechanism of Action
The active ingredient of the drug mainly acts by binding to a protein which causes inflammation and inhibits the inflammatory response which plays a role in plaque psoriasis.
The efficacy and safety of brodalumab drug were established in three randomized, placebo-controlled clinical trial on 4,373 participants who have moderate-severe plaque psoriasis who were eligible for systemic therapy or phototherapy.
The results of the clinical trial conducted on patients who took brodalumab drug were compared to the patients who took placebo. More number of patients who took brodalumab drug were found to have a clear or almost clear skin when compared to the placebo. This was assessed by scoring the extent, nature and severity of the skin changes.
Risk of Suicidal Ideation and Behavior
The patients who were treated with brodalumab drug in clinical trials had a risk of suicidal ideation and behavior. These users with a history of suicidality or depression may further have an increased risk of suicidal ideation or behavior.
Due to the observed risk, the labeling for brodalumab drug includes a boxed warning and the drug can be available only through the Risk Evaluation and Mitigation Strategy (REMS)
The requirements of the Brodalumab Risk Evaluation and Mitigation Strategy (REMS) Program include
- Physicians who prescribe the drug must be certified with the program and must counsel patients about the risk. The patients have to be referred to a mental health professional if there are any new or worsening symptoms of depression or suicidality.
- A patient-prescriber agreement form has to be signed by the patient and they must be aware of the need for medical attention as they can experience new or worsening symptoms or changes in the mood.
- The pharmacies must also be certified and must dispense the drug to only authorized patients who receive brodalumab drug.
- Joint pain
- Throat pain
- Muscle Pain
- Low white blood cell count
- Fungal infections
Note: The drug must not be injected to patients who have active tuberculosis infections.
They must avoid immunizations with live vaccines when treated with brodalumab drug
Facts on Psoriasis
- Psoriasis occurs commonly in patients who are with a family history of the disease.
- People between the age of 15 and 35 years are more prone to psoriasis.
- The common form of psoriasis is plaque psoriasis where the patient skin is accompanied with redness and flaky silver-white scales.
- Around 11% of people diagnosed with psoriasis are also being diagnosed with psoriatic arthritis.
- It is estimated that around 20,000 children below 10 years of age are diagnosed with psoriasis every year.
- About Psoriasis - (https://www.psoriasis.org/about-psoriasis)
- FDA approves new psoriasis drug - (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm)